Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 706

    1.

    Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.

    Camporota L, Corno E, Menaldo E, Smith J, Lei K, Beale R, Wyncoll D.

    Crit Care. 2008;12(6):R163. Epub 2008 Dec 18.

    PMID:
    19094233
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

    Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

    Crit Care Med. 2008 Jan;36(1):14-23.

    PMID:
    18158435
    [PubMed - indexed for MEDLINE]
    3.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

    Surgery. 2007 Apr;141(4):548-61.

    PMID:
    17431957
    [PubMed - indexed for MEDLINE]
    4.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

    Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61.

    PMID:
    17084715
    [PubMed - indexed for MEDLINE]
    5.

    Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis.

    de Pont AC, Schultz MJ.

    Crit Care. 2009;13(1):113. Epub 2009 Feb 2. Review.

    PMID:
    19226446
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.

    Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, Beale R.

    Crit Care. 2009;13(3):R103. Epub 2009 Jun 30.

    PMID:
    19566927
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    7.

    Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

    Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group.

    Lancet. 2007 Mar 10;369(9564):836-43.

    PMID:
    17350452
    [PubMed - indexed for MEDLINE]
    8.

    Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.

    Ernst FR, Johnston JA, Pulgar S, He J, Ball DE, Young JK, Cooper LM.

    Curr Med Res Opin. 2007 Jan;23(1):235-44.

    PMID:
    17207305
    [PubMed - indexed for MEDLINE]
    9.

    Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.

    Vincent JL, Nadel S, Kutsogiannis DJ, Gibney RT, Yan SB, Wyss VL, Bailey JE, Mitchell CL, Sarwat S, Shinall SM, Janes JM.

    Crit Care. 2005 Aug;9(4):R331-43. Epub 2005 May 17.

    PMID:
    16137345
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    10.

    Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).

    Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J.

    Crit Care. 2008;12(2):R45. Epub 2008 Apr 4. Review.

    PMID:
    18394162
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    11.

    The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

    Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2004 Nov;32(11):2199-206.

    PMID:
    15640631
    [PubMed - indexed for MEDLINE]
    12.

    Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.

    Levy M, Levi M, Williams MD, Antonelli M, Wang D, Mignini MA.

    Intensive Care Med. 2009 Jul;35(7):1196-203. Epub 2009 Apr 15. Erratum in: Intensive Care Med. 2009 Jul;35(7):1322-3.

    PMID:
    19367397
    [PubMed - indexed for MEDLINE]
    13.

    Drotrecogin alfa (activated): real-life use and outcomes for the UK.

    Rowan KM, Welch CA, North E, Harrison DA.

    Crit Care. 2008;12(2):R58. Epub 2008 Apr 22.

    PMID:
    18430215
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

    Barie PS, Hydo LJ, Shou J, Eachempati SR.

    Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.

    PMID:
    16895513
    [PubMed - indexed for MEDLINE]
    15.

    Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

    N Engl J Med. 2005 Sep 29;353(13):1332-41.

    PMID:
    16192478
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

    Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group.

    Am J Respir Crit Care Med. 2007 Sep 1;176(5):483-90. Epub 2007 Jun 7.

    PMID:
    17556722
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.

    Vincent JL, Laterre PF, Decruyenaere J, Spapen H, Raemaekers J, Damas F, Rogiers P, Sartral M, Haentjens T, Nelson D, Janes J.

    Acta Clin Belg. 2008 Jan-Feb;63(1):25-30.

    PMID:
    18386762
    [PubMed - indexed for MEDLINE]
    18.

    Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

    Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL.

    Crit Care. 2003 Apr;7(2):155-63. Epub 2003 Feb 28. Review.

    PMID:
    12720562
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    19.

    Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.

    Hodder RV, Hall R, Russell JA, Fisher HN, Lee B.

    Crit Care. 2009;13(3):R78. Epub 2009 May 20.

    PMID:
    19457240
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.

    Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC.

    Crit Care Med. 2004 Nov;32(11):2207-18.

    PMID:
    15640632
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk